The LUNA 3 trial demonstrated a statistically significant durable platelet response at week 25 in 23% of patients receiving Wayrilz versus none in the placebo group (p<0.0001). How do you interpret the clinical relevance of this result for managing persistent and chronic ITP?

Patients on Wayrilz achieved their first platelet response in a median of just 36 days compared to no measurable response in the placebo arm. In practice, how critical is this faster time to response for preventing bleeding risks and improving patient safety early in treatment?

Wayrilz operates via BTK inhibition with a multi-immune modulation approach. How does targeting multiple immune pathways differentiate this therapy from traditional ITP treatments like corticosteroids, IVIG, or TPO receptor agonists?

The study reported a 10.6-point improvement in health-related quality-of-life measures for Wayrilz patients versus only 2.3 points in the placebo group. How meaningful are these patient-reported outcome improvements when evaluating a therapy’s overall benefit in ITP?

Given that Wayrilz is approved for adults with an insufficient response to previous therapies, where do you see it fitting in current ITP treatment sequencing, especially for patients who fail corticosteroids, TPO-RAs, or rituximab?

The most common adverse events included diarrhea, nausea, headache, abdominal pain, and COVID-19, with no new safety signals emerging. How would you assess the overall safety and tolerability profile of Wayrilz compared to existing therapies for long-term ITP management?

Wayrilz has also received orphan drug designations for other rare diseases, including wAIHA, IgG4-related disease, and sickle cell disease. Do you see its BTK inhibition mechanism potentially transforming treatment options across multiple autoimmune and hematologic conditions?

With Wayrilz now the first FDA-approved BTK inhibitor for ITP, how do you envision its approval influencing clinical practice, future guideline recommendations, and competition among emerging therapies in this space?